This page shows the latest medicines value news and features for those working in and with pharma, biotech and healthcare.
Natsis believes this is a pointer to the future direction of medicines pricing and reimbursement in Europe. ... PME: How do Europe’s healthcare systems need to evolve? EFPIA:Our current system means the costs are borne in year one from the medicines
This will include how it should deal with uncertainty around clinical and cost effectiveness data for new medicines at launch. ... This review is a critical opportunity to ensure NICE’s methods are fit for the future and suitable for assessing the
cost and value of the drug, which has a list price of £104, 000 ($136, 000) per patient per year. ... to capture the full value of specialist medicines for small populations.
able to access new and innovative medicines as early as possible and delivering better value for money.”. ... Outcome-based pricing could help the NHS get better value from new medicines and help our members better understand how treatments are
However, Vertex rejected this offer, saying it “fails to adequately reflect the value of our current and future medicines and the number of patients that will be treated with these medicines". ... Other pharmaceutical companies are working
Ahmad adds: “NICE does not consider impact of diseases on broader society when evaluating the cost-effectiveness of medicines. ... We believe this fails to capture the true value of medicines like Aimovig.
More from news
Approximately 2 fully matching, plus 126 partially matching documents found.
In recent years, PSPs have proved instrumental in securing payer support and market access, with companies increasingly wrapping support services around their medicines to provide value beyond the pill. ... But they have to be built with that value in
Reflecting back, the five-year anniversary of biosimilars in the US marks an occasion to celebrate the value these high-quality, more affordable medicines have added to health systems and patient ... and value of biosimilar medicines.
of therapies, the ability of medications to offset other healthcare costs, and the value of innovative medicines.
Abasaglar – a biosimilar to Lantus (diabetes), offering a money-saving value proposition for medicines management. ... Sirdupla – a branded generic to Seretide (asthma), offering good cost savings for medicines management.
In contrast, the value of medicines bought by the commercial or private healthcare sector was 991bn roubles in 2018, up from 948bn the previous year. ... The Russian market is dominated by generic drugs. Only 14.4% of medicines sold in the country in
More from intelligence
Approximately 1 fully matching, plus 49 partially matching documents found.
grow this company into a very excising and meaningful entity that has the potential to create both important new medicines for patients and generate significant value for shareholders.".
April. In his new role, Dr Liu will be responsible for all of the Paris-based pharmaceutical company's research and will be tasked with delivering innovative and high-value medicines.
the access to and use of new and innovative medicines for Scottish patients. . ... The ABPI Scotland team is fully committed to working with all of our stakeholders to support a common understanding and appreciation of the life-saving and life-enhancing
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Its capabilities provide a comprehensive temperature-controlled solution for high-value and/or irreplaceable regenerative medicines and biopharmaceuticals in a cryogenic or temperature-controlled state. ... They are the third largest healthcare
its state-of-the-art nanotechnology to develop high value medicines where a reduced dose and improved drug delivery is needed, to overcome existing efficacy, tolerability and safety profile concerns.
Before rotating into this practice, I spent the first year of the scheme working with OPEN Value, Informatics &Evidence (OPEN VIE), completing a 6-month rotation in market access followed by ... Getting to experience two disciplines within OPEN VIE was a
The inclusion of innovative medicines in the WHO EML is an important step to help patients gain access to effective treatments. ... According to the WHO, more than 150 countries use the EML to guide decisions about which medicines represent the best
by 2020/21 if the NHS embraces the use of best value biological medicines in a proactive, systematic and safe way’. ... needs to redefine its value proposition and move the focus away from direct medicines costs to demonstrating how savings can be made
More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...